Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
<p>Abstract</p> <p>Background</p> <p>Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of patients with...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-10-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/426 |
id |
doaj-ddfd4d311b91470ab57dc2216397c6ec |
---|---|
record_format |
Article |
spelling |
doaj-ddfd4d311b91470ab57dc2216397c6ec2020-11-25T01:03:06ZengBMCBMC Cancer1471-24072011-10-0111142610.1186/1471-2407-11-426Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?Bedard PhilippeChen Eric XWang LisaChan Kelvin KFlorescu AnaChau Nicole GOza Amit MSiu Lillian L<p>Abstract</p> <p>Background</p> <p>Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of patients with advanced solid malignancies are difficult to predict.</p> <p>Methods</p> <p>We analyzed 233 patients who were enrolled in PIT at Princess Margaret Hospital. We assessed the relationship between 17 clinical characteristics and 90DM using univariate and multivariate logistic regression analyses to create a risk score (PMHI). We also applied the Royal Marsden Hospital risk score (RMI), which consists of 3 markers (albumin < 35g/L, > 2 metastatic sites, LDH > ULN).</p> <p>Results</p> <p>Median age was 57 years (range 21-88). The 90DM rate was 14%; median OS was 320 days. Predictors of 90DM were albumin < 35g/L (OR = 8.2, p = 0.01), > 2 metastatic sites (OR = 2.6, p = 0.02), and ECOG > 0 (OR = 6.3, p = 0.001); all 3 factors constitute the PMHI. To predict 90DM, the PMHI performed better than the RMI (AUC = 0.78 vs 0.69). To predict OS, the RMI performed slightly better (RMI ≥ 2, HR = 2.2, p = 0.002 vs PMHI ≥ 2, HR = 1.6, p = 0.05).</p> <p>Conclusions</p> <p>To predict 90DM, the PMHI is helpful. To predict OS, risk models should include ECOG > 0, > 2 metastatic sites, and LDH > ULN. Prospective validation of the PMHI is warranted.</p> http://www.biomedcentral.com/1471-2407/11/426 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bedard Philippe Chen Eric X Wang Lisa Chan Kelvin K Florescu Ana Chau Nicole G Oza Amit M Siu Lillian L |
spellingShingle |
Bedard Philippe Chen Eric X Wang Lisa Chan Kelvin K Florescu Ana Chau Nicole G Oza Amit M Siu Lillian L Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer |
author_facet |
Bedard Philippe Chen Eric X Wang Lisa Chan Kelvin K Florescu Ana Chau Nicole G Oza Amit M Siu Lillian L |
author_sort |
Bedard Philippe |
title |
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
title_short |
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
title_full |
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
title_fullStr |
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
title_full_unstemmed |
Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
title_sort |
early mortality and overall survival in oncology phase i trial participants: can we improve patient selection? |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2011-10-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of patients with advanced solid malignancies are difficult to predict.</p> <p>Methods</p> <p>We analyzed 233 patients who were enrolled in PIT at Princess Margaret Hospital. We assessed the relationship between 17 clinical characteristics and 90DM using univariate and multivariate logistic regression analyses to create a risk score (PMHI). We also applied the Royal Marsden Hospital risk score (RMI), which consists of 3 markers (albumin < 35g/L, > 2 metastatic sites, LDH > ULN).</p> <p>Results</p> <p>Median age was 57 years (range 21-88). The 90DM rate was 14%; median OS was 320 days. Predictors of 90DM were albumin < 35g/L (OR = 8.2, p = 0.01), > 2 metastatic sites (OR = 2.6, p = 0.02), and ECOG > 0 (OR = 6.3, p = 0.001); all 3 factors constitute the PMHI. To predict 90DM, the PMHI performed better than the RMI (AUC = 0.78 vs 0.69). To predict OS, the RMI performed slightly better (RMI ≥ 2, HR = 2.2, p = 0.002 vs PMHI ≥ 2, HR = 1.6, p = 0.05).</p> <p>Conclusions</p> <p>To predict 90DM, the PMHI is helpful. To predict OS, risk models should include ECOG > 0, > 2 metastatic sites, and LDH > ULN. Prospective validation of the PMHI is warranted.</p> |
url |
http://www.biomedcentral.com/1471-2407/11/426 |
work_keys_str_mv |
AT bedardphilippe earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT chenericx earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT wanglisa earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT chankelvink earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT florescuana earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT chaunicoleg earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT ozaamitm earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection AT siulillianl earlymortalityandoverallsurvivalinoncologyphaseitrialparticipantscanweimprovepatientselection |
_version_ |
1725202384946200576 |